AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.
Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.
It also serves government institutions, contract research organizations, and synthetic biology companies.
The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020.
Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Country | United States |
IPO Date | Jun 18, 2021 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 137 |
CEO | Eric Esser |
Contact Details
Address: 29 Hartwell Ave Lexington, MASSACHUSETTS United States | |
Website | https://codexdna.com |
Stock Details
Ticker Symbol | TBIO |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001693415 |
CUSIP Number | 89374L104 |
ISIN Number | US1920031010 |
Employer ID | 61-1807780 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Eric Esser | President, Chief Executive Officer, Chief Operating Officer & Chairman |
Daniel G. Gibson Ph.D. | Chief Technology Officer |
William J. Kullback | Chief Financial Officer |
Decky Goodrich M.B.A. | Senior Vice President of Corporate Development |
Jen Carroll | Vice President of Investor Relations |
Richard Lepke | Director of Investor Relations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 24, 2021 | 15-12B | Filing |
Sep 21, 2021 | EFFECT | Filing |
Sep 21, 2021 | EFFECT | Filing |
Sep 16, 2021 | 4/A | [Amend] Filing |
Sep 16, 2021 | SC 13D/A | [Amend] Filing |
Sep 14, 2021 | 4 | Filing |
Sep 14, 2021 | 4 | Filing |
Sep 14, 2021 | 4 | Filing |
Sep 14, 2021 | 4/A | [Amend] Filing |
Sep 14, 2021 | 4 | Filing |